) recently announced that the US Food and Drug Administration
(FDA) accepted its New Drug Application (NDA) for macitentan.
Actelion is looking to get macitentan approved in the US as a
treatment for patients suffering from pulmonary arterial
Actelion had submitted the NDA in October 2012. The US
regulatory body is expected to review the application for 12
months from the date of submission, which means a response should
be out by the fourth quarter of 2013.
The company conducted a long-term, event-driven phase III
outcome study, SERAPHIN, with macitentan. Results from the study
revealed that treatment with macitentan (10mg once daily) reduced
the risk of morbidity and mortality by 45% compared to placebo.
The risk was reduced by 30% in PAH patients treated with the 3 mg
dosage of the drug.
We note that in November this year the European Medicines
Agency (EMA) accepted Actelion's Marketing Authorisation
Application (MAA) for macitentan.
Actelion currently has three marketed products, Tracleer,
Ventavis and Veletri, for the treatment of PAH. We remind
investors that during the first nine months of 2012 the company
reported a decline in sales of Tracleer and Ventavis from the
year-ago period. Veletri, launched in 2010, however did very well
during this period.
Actelion currently competes with players such as
) in the PAH space. We believe that if macitentan is cleared in
the US and the EU, Actelion's position in the PAH market would be
Actelion carries a Zacks #1 Rank (Strong Buy) in the short run
whereas United Therapeutics carries a Zacks #2 Rank (Buy).
(ALIOF): ETF Research Reports
GILEAD SCIENCES (GILD): Free Stock Analysis
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.